Credit Suisse places outperform rating with $7.00 price target.
We are Initiating Coverage of XenoPort with an Outperform Rating and $7 Target Price. Despite a number of fundamental concerns, at its current valuation ($219mn market cap/$165mn y/e EV) and with low expectations for its marketed products and pipeline, we think relatively little has to go right for the stock price to appreciate. Specifically we see 3 main upside optionality triggers which are not factored into our numbers/valuation (a) delivery of greater Regnite/Horizant revenues – either via high end-user sales and/or US re-partnering (b) monetization of clinical assets, in particular XP23829 or (c) the company seeks strategic alternatives.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.